A Phase 2/3 interventional study of Ecopipam 50mg and Ecopipam 100mg in Stuttering, Adult, Childhood-onset Fluency Disorder and Speech Disorders, sponsored by Gerald Maguire, MD. Status unknown at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-10-26.
Sponsored by Gerald Maguire, MD · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Stuttering with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Stuttering · United States.
Among the 35 studies in Stuttering with a site in United States, this one is the 25th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 2/3, and was the 12th registered.
74 studies on the registry are indexed under Stuttering; 23 are open to participants now.
Browse Stuttering studies →17 of the 35 studies in Stuttering with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18–65
Boston University Charles River Campus · Sites in United States
Ages 18–50 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18–50
University of Michigan · Sites in United States
Ages 18–65
CSTrials Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Stuttering studies recruiting now, 3 (16%) set no upper age limit and 15 (79%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3
First in 1992; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 44 across 57 interventional studies indexed under Stuttering.
Median enrollment 68 across the 27 interventional studies, 411 across the 7 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 35 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Gerald Maguire, MD as lead sponsor.
Gerald Maguire, MD has 1 study filed under Stuttering — fewer than ten, so there is no comparison to draw.
6 of the studies in Stuttering with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354139The University of Texas at DallasUsing Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter | 2027-02-28 |
| NCT06578416Michigan State UniversityThe Development of Stuttering in Young Children | 2027-06 |
| NCT07215884University of California, San FranciscoDopamine and Sensorimotor Function in Stuttering | 2027-06-30 |
| NCT07734103CSTrials Inc.Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder | 2027-07-31 |
| NCT07668882University of MichiganNoninvasive Thalamocortical Neuromodulation With Low-Intensity Focused Ultrasound for Persistent Developmental Stuttering | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 35 studies in Stuttering with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms.
It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects can be enrolled in the study only if they meet all of the following criteria:
Exclusion Criteria:
Subjects will be excluded from the study for any of the following reasons:
It is the investigator's opinion that the subject poses a significant suicide risk by the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
Drug: Ecopipam 50mg · Drug: Ecopipam 100mg
If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
Drug: Ecopipam 50mg · Drug: Ecopipam 100mg
Change in the Stuttering Severity Instrument Version IV (SSI-IV)
This is an objective measure of stuttering in which it captures verbal samples of five minutes speaking during a conversation and 5 minutes of reading a passage.
Time frame: This scale is completed on Visit 1/screening and Visit 5/week 8.
Clinical Global Impression Scale-Severity (CGI-S)
This is an evaluation of the patient by the investigator as to whether or not the subjects has improved, remained the same, or worsened while in the study.
Time frame: This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, and Visit 5/week 8.
Subjective Stuttering Scale (SSS)
Time frame: This scale is completed on Visit 2/baseline and Visit 5/week 8.
Overall Assessment of the Speaker's Experience of Stuttering (OASES)
Time frame: This scale is completed on Visit 2/baseline and Visit 5/week 8.
Montgomery Asberg Depression Rating Scale (MADRS)
An observer-rated depression scale
Time frame: This scale is completed on Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8.
Barnes Akathisia Scale (BAS)
measures how restless the subject is during the examination
Time frame: This scale is completed on Visit 1/screening, Visit 5/week 8.
Abnormal Involuntary Movement Scale (AIMS)
Time frame: This scale is completed on Visit 1/screening, Visit 5/week 8.
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8.
Simpson Angus Scale (SAS)
Time frame: This scale is completed on Visit 1/screening, Visit 5/week 8.
The record gives a start of Sep 2016, a primary completion of Aug 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecopipam